Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Mirikizumab Formulations in Healthy Subjects
NCT03053622Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration Versus Time Curve From 0 to Infinity at 2016 hours. Started Apr 2017; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03053622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053622.